Catheter ablation for ventricular tachycardia and premature ventricular complexes (PVCs) is common. Catheter ablation of atrial fibrillation is associated with a risk of cerebral emboli attributed to cardioversions and numerous ablation lesions in the low-flow left atrium, but cerebral embolic risk in ventricular ablation has not been evaluated.
T he prevalence of endocardial ablation as a treatment method for various cardiac arrhythmias is growing, with well >235 000 ablations performed annually. Endocardial catheter ablation of the left and right ventricles primarily for ventricular tachycardia (VT) comprises ≈7% of ablations in the United States, a proportion that is expected to increase. [1] [2] [3] Furthermore, there is growing evidence that premature ventricular complexes (PVCs) may be a more common cause of systolic dysfunction than had been realized, and thus the number of patients considered for PVC ablation will likely also substantially increase. [4] [5] [6] [7] [8] Early research into the risks associated with diagnostic aortic valve procedures demonstrated new asymptomatic cerebral emboli in 22% of patients with the use of MRI. These lesions were attributed to disruption of debris from the degenerative aortic valves because of multiple attempts to cross the valve with a wire. 9 Coronary angiography was then shown to be associated with the same phenomenon in ≈10% of patients, potentially related to the vascular disease common in patients with coronary disease or emboli related to the frequent exchange of materials through the diagnostic catheters. 10 Subsequently, the development of cerebral emboli after atrial fibrillation (AF) ablation was established, ranging from ≈6% to 38% of all cases. [11] [12] [13] [14] [15] Risk factors included duration of radiofrequency ablation, suggesting that the uniquely large number of ablation lesions in AF ablation might be important, and intraprocedural cardioversion, signifying left atrial appendage stunning as being at least partly responsible. 12, [16] [17] [18] It is important to note that although these embolic infarcts were initially thought to be subclinical, ensuing investigation has demonstrated they may have negative neurocognitive effects. [19] [20] [21] Unlike diagnostic catheterbased procedures for aortic valve disease, left ventricular (LV) ablation procedures are often performed in patients with normal valves. Unlike coronary angiography, there is generally no injection of any material directly into the left side of the heart and, in comparison with AF ablation, the number of lesions in many LV ablation procedures is fewer, the ventricle is a higher-flow and a more dynamic chamber, and cardioversion is generally not relevant. However, given the growing number of LV ablations, particularly in light of the growing popularity of ablation among otherwise healthy patients with PVCs, we sought to determine whether any risk of cerebral embolism might be present.
METHODS
We sought to determine whether cerebral emboli identified by comparing pre-and postprocedural diffusion-weighted MRI (DWI-MRI) of the brain occur after LV endocardial ablation. We prospectively screened the charts of consecutively scheduled ventricular ablations at our center for eligible patients. Patients were excluded for an age <18 years, contraindication to MRI, the presence of implantable cardioverter defibrillator or permanent pacemaker, or the inability to provide informed consent.
To test the hypothesis that some proportion of cerebral emboli would be observed specifically in the retrograde approach (via the femoral artery, through the aorta and the aortic valve to reach the LV) and on the basis of rates observed in previous left-heart procedures (generally 10%-20%), [9] [10] [11] [12] [13] [14] [15] we sought to enroll all consenting consecutive patients scheduled for PVC or VT ablations without any of the exclusion criteria (as above) until at least 10 purely retrograde LV procedures had been completed (to detect if at least 1 in 10 such patients experienced a new cerebral embolus).
Once identified as eligible and consented to enroll, participants underwent DWI-MRI of the brain within 1 week of their scheduled ablation. This included 3D T2 cube fluid-attenuated inversion recovery (FLAIR) imaging and axial and coronal planes DWI-MRI (GE Healthcare 750 3T, 24X software platform) with the following characteristics: FLAIR -repetition time/echo time/inversion time=5800 ms/117.5 ms/1560 ms, echo train length 160, matrix 256×256, slice thickness 1.1 mm, field of view 24 cm, scan time ≈6.5 minutes; axial DWI imaging -repetition time/echo time=12s/minimum, b=1000 s/mm 2 , 3 directions, number of excitations=4, matrix=112×140, slice thickness 2 mm, field of view 24 cm, scan time ≈2.4 minutes; coronal DWI imaging -repetition time/echo time=12s/minimum, b=1000 s/mm 2 , 3 directions, number of excitations=4, matrix=100×90, field of view 24 cm, scan time ≈2.4 minutes. On the first postprocedural day, a repeat DWI-MRI of the brain using the same protocol was obtained.
The MRIs were interpreted by a board-certified neuroradiologist blinded to the details of the patient's clinical condition and procedure. A complete neurological examination was performed at the time of the pre-and postprocedural DWI-MRIs by a physician or research coordinator trained in neurological examination. Before initiation of the study, the following protocol was established on the basis of recommendations from expert neurology colleagues: in the event of positive asymptomatic DWI-MRI findings, patients were started on aspirin 81
Clinical Perspective
What Is New?
• Brain imaging with diffusion-weighted MRI of patients undergoing left ventricular endocardial ablation demonstrated a significant risk of brain emboli, even in the absence of clinically apparent stroke.
What Are the Clinical Implications?
• The long-term consequences of subclinical emboli to the brain are unknown. Given their prevalence in patients undergoing left ventricular endocardial ablation, their long-term effects should be addressed by future research.
• Future research should elucidate risk factors for brain emboli and the optimal strategies to prevent brain emboli associated with left ventricular endocardial ablation.
mg daily if not already taking it and referred to the Neurology Clinic as an outpatient. Any neurological deficits or symptoms would trigger an immediate assessment by a neurologist. On the day of the ablation, all patients were evaluated by an anesthesiologist before the procedure. Decisions regarding the use of general anesthesia before the procedure, management of intraprocedural sedation, and dosing of intraprocedural anticoagulation were made by the electrophysiology attending physician. Decisions regarding vascular access and, in patients undergoing LV ablation, approach to the LV (ie, retrograde aortic versus transseptal) were made on the basis of clinical grounds. Participants underwent standard VT or PVC ablation procedures. All cases were performed with a cardiac electrophysiology fellow. Venous access was obtained using ultrasound and micropuncture approaches. Transseptal punctures were performed under intracardiac ultrasound and fluoroscopic guidance. Standard dosing of all intraprocedural medications was used, including heparin dosing on the basis of weight. Heparin was infused before any LV access, and heparin dosing and activated clotting times were recorded with a goal-activated clotting time of 300 to 400 seconds. Standard sheaths and irrigated-tip catheters (SmartTouch, Biosense; TactiCath, St. Jude Medical) for ventricular ablation were used in a power-controlled system (up to 40 W) and an irrigation rate using 0.9% heparinized saline of 20 to 35 mL/min to maintain a tip temperature of <45°C. The CARTO (Biosense) and EnSite NavX (St. Jude Medical) mapping systems were used for each case. All left-sided ablations using a retrograde aortic approach underwent a femoral angiogram (primarily to assess for the suitability of closure device placement). A board-certified interventional cardiologist with expertise in peripheral vascular disease who was blinded to all outcomes reviewed all the femoral angiograms for evidence of vascular disease.
The study was approved by the University of California, San Francisco Institutional Review Board. All patients gave informed consent.
Statistical Analysis
All analyses were performed using STATA version 13.0. Demographic and baseline characteristics were described by using means with standard deviations. The postprocedural cerebral embolic burden was quantified in comparison with preprocedural DWI-MRI findings, and comparisons between groups were performed using the Fishers Exact Test or Students t test, as appropriate. A 2-tailed P value of <0.05 was considered significant.
RESULTS
We screened 119 patients scheduled for PVT or VT ablation between November 2014 and May 2016, with 18 ultimately included in the study ( Figure 1 ). LV ablation (10 for PVC and 2 for VT) was performed in 12 patients (retrograde only and crossing the aortic valve in 10, both retrograde and transseptal in 1, and transseptal only in 1) and right ventricle-only ablation in 6 patients (5 for PVC and 1 for VT). In patients undergoing LV versus right ventricle ablation, there were no detectable differences in patient characteristics (Table 1) . Patients undergoing LV ablation had longer procedures. In the LV ablation group, 16 new cerebral emboli were identified in 7 patients (58% of all LV patients) (Figure 2 ), in comparison with zero in the right ventricle ablation group (P=0.04). None of the patients were symptomatic and none of the pre-or post-physical examinations revealed any new neurological deficits. Those with cerebral emboli all underwent retrograde aortic approaches (64% of retrograde procedures, and excluding 1 patient who underwent a transseptal approach as well, 70% of all purely retrograde procedures). Patients with new brain emboli had higher intraprocedural minimum systolic blood pressure (Table 2 ), but no other procedural characteristics were associated with a higher risk. There were no statistically significant associations between proceduralactivated clotting time values or protamine dosing and development of brain emboli (online-only Data Supplement Table I ). None of the femoral angiograms of patients undergoing retrograde aortic procedures revealed any evidence of peripheral vascular disease (online-only Data Supplement Figure I ). Only 1 patient underwent intraprocedural cardioversion, and that patient had no postprocedural cerebral emboli. The regions ablated in those undergoing LV ablation are depicted in Figure 3 , and no regional pattern was detected in association with occurrence of cerebral emboli.
DISCUSSION
Performing DWI-MRI on 18 consecutive patients meeting study inclusion criteria and using a standard approach to ventricular ablation, we found that more than half of the patients developed new asymptomatic brain emboli related to the LV ablation procedure. Seven of 11 patients undergoing a retrograde aortic approach to the LV developed postprocedural cerebral emboli by MRI. The dramatic incidence of brain emboli was surprising, because it was higher than that seen with AF ablation despite being in a higher-flow chamber with substantially fewer radiofrequency burns, and because the great majority of patients were relatively healthy and only undergoing PVC ablations. This important finding underscores questions regarding the etiology of these emboli, their potential sequelae, and best practice for LV endocardial ablation.
That a minority of patients undergoing AF ablation experience new brain lesions is now well established. [11] [12] [13] [14] [15] Although the incidence of clinically apparent cerebral emboli (ie, stroke) after AF ablation is <2%, 12,22 the incidence of subclinical emboli detected by brain MRI occurs in up to 6% to 38% of cases. [11] [12] [13] [14] [15] 17, 23 However, there are several characteristics inherent to AF ablation that are not applicable to LV ablation procedures. AF itself, and particularly cardioversion, is associated with stroke (because of preexisting thrombi in the left atrial appendage or subsequent formation of thrombi during postcardioversion stunning). Although severely dilated left ventricles may also harbor thrombi, this is generally not relevant in patients with predominately idiopathic PVCs or VT, and none of our patients had an ejection fraction <35%. AF ablation often involves considerable left atrial time and not infrequently can include >50 or even >100 ablation lesions. In contrast, the average number of LV lesions in our study was <10. Last, the high-flow chamber of the LV has generally been thought to be less prone to thrombus formation than the lowflow left atrium, which might be more prone to clots related to stagnant blood flow. Conversely, previous literature regarding diagnostic catheters (outside the realm of electrophysiology and not involving ablation), such as during aortic valve studies 9 and coronary angiography involving a retrograde aortic approach, 10 have also exhibited a risk of cerebral emboli. However, simply crossing the aortic valve with a diagnostic catheter was associated with a 22% incidence of new brain emboli, and, because this was done only in patients with aortic stenosis, this observation has largely been attributed to pathology of the aortic valve and associated debris that may easily embolize. Among patients undergoing coronary angiography, 10% exhibited new brain lesions, but, unlike with catheter ablation, there is direct injection of material, which itself may pose unique risk.
The incidence of new brain lesions among our patients is therefore striking, because many factors previously thought to be causes of brain emboli in catheterbased cardiac procedures are less relevant in our study patients, and the patients were relatively healthy. The incidence of stroke stemming from LV ablation is rare, similar to that occurring with AF ablation, and has typically been observed in populations with relatively prevalent ischemic cardiomyopathy with severe systolic dysfunction and chronic kidney disease. 24, 25 Indeed, the majority of patients in our study underwent LV ablation for PVCs, which are typically treated in lower-risk patients with less significant underlying cardiac disease and generally require fewer ablation applications than in those with VT. Furthermore, in contrast to typical patients undergoing ventricular ablation, the patients in our study undergoing LV ablation had a prevalence of only 50% of hypertension or hyperlipidemia, and were relatively free of diabetes mellitus, coronary disease, heart failure, and atrial fibrillation. No patients had chronic kidney disease or a history of peripheral vascular disease, and an examination of all femoral angiograms for those undergoing retrograde LV procedures revealed no evidence of peripheral vascular disease. In fact, PVC patients are arguably the lowest possible risk group undergoing LV ablation. Yet, over half of patients in the study experienced cerebral emboli, including 60% of those undergoing PVC ablation.
The patients in the present study were, on average, healthier than the typical patient undergoing LV ablation, suggesting that the risk of emboli in patients with ischemic VT and dilated cardiomyopathies may be even higher. The common presence of implantable cardioverter defibrillators in these less healthy groups poses a unique challenge given safety concerns regarding MRI procedures. However, with increasing evidence that MRIs are safe for patients with implantable cardioverter defibrillators, these challenges may diminish. 26, 27 The brain emboli detected only by MRI after catheter-based and cardiac surgical procedures were initially thought to be entirely subclinical in the absence of obvi- †No study participants had a history of chronic kidney disease, peripheral vascular disease, deep venous thrombosis, pulmonary embolism, or coagulopathy. No participants had aortic stenosis or evidence of aortic disease or tortuosity by echocardiogram.
‡ All participants with smoking history were former smokers. §By echocardiogram within 15 months before or up to 7 months after the index procedure.
ous neurological deficits. 10, 28, 29 However, debate exists as to whether they may have negative neurocognitive effects, including influence on executive function, visual and auditory learning, attention, psychomotor speed, and memory. [19] [20] [21] 30, 31 Although the presence of cerebral emboli and neurocognitive decline after cardiac surgery is well described, the 2 phenomena have not been uniformly associated with one another. 21, 31 However, in a study evaluating patients undergoing intracardiac procedures only (ie, valve surgery, excluding bypass surgery) and excluding patients with prevalent mood disorders, cognitive decline was associated with the presence of postoperative cerebral emboli and worsening cognitive function correlated with increasing postoperative cerebral embolic burden. 20 In the single study to date in the AF literature examining postprocedural neurocognitive performance, a decline in neurocognitive function was observed in 13% to 20% of patients undergoing pulmonary vein isolation for paroxysmal and persistent AF, respectively, the majority of whom had CHADS 2 scores of 0 to 1.
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Although these patients did not undergo MRI to correlate these neurocognitive findings with cerebral embolism, the decline was statistically greater than those undergoing ablation for supraventricular tachycardia or those with AF awaiting ablation, suggesting that some procedural effect related to left atrial ablation is the likely culprit. Fortunately, evidence does suggest that >80% of the cerebral emboli detected by MRI shortly after the procedure resolve on follow-up MRI weeks later. 11, 14 However, this stands in contrast to the persistence of the neurocognitive effects, which may be long lasting. 19 In fact, cerebral tissue necrosis may persist even after resolution of radiological lesions, and neurological and cognitive deficits can persist despite normal DWI-MRI. [32] [33] [34] The exact etiology of these brain lesions remains unclear. The AF ablation literature demonstrates that the type of ablation catheter can be important, 13, 15 suggesting that emboli originating from the eschar at the site of ablation lesions may be implicated. [35] [36] [37] [38] Prior literature has demonstrated intraprocedural cardioversion to be a risk factor for in AF ablation 12, 16, 17 ; however, only 1 patient underwent intraprocedural cardioversion in the present study despite a high rate of postprocedural cerebral emboli (and the absence of postprocedural cerebral embolus in that single patient). The incidence of cerebral emboli has been shown to diminish with AF ablation performed on therapeutic warfarin, arguing that embolization of thrombus plays an important role. 39 It is noteworthy that we found no statistically significant relationships between activated clotting time measurements and brain emboli; the only relationship that neared statistical significance (P=0.05) revealed a trend toward more subtherapeutic time in those without the development of emboli. It is important to note that although the ablation itself is always performed using high-dose heparin, the conventional approach has been to reverse the heparin effect at the end of the procedure to achieve hemostasis at the access sites. Therefore, the on-warfarin procedures may offer a protective effect in the period after reversal of anticoagulation, but this has not become common practice for LV ablations. Indeed, because these cases often involve femoral arterial access, there may be a greater reluctance to perform such procedures on therapeutic anticoagulation. Air entrained through the catheter, tissue from transseptal puncture, or calcium or plaque from valves may also play a role in the pathogen- esis of procedurally related cerebral embolism observed in the current study. [9] [10] [11] [12] [13] [14] [15] The data from diagnostic procedures using a retrograde aortic approach suggests that dislodgment of debris, either aortic atheroma or material on the aortic valve, may be especially important. 9, 10 However, only 2 patients in our study had either aortic sclerosis or aortic vascular disease by echocardiogram or by history (none had aortic stenosis), 1 of whom was found to have a cerebral embolus. Although only one of our patients underwent LV ablation via a purely transseptal approach, it is interesting to note that all cerebral emboli were detected in patients undergoing a retrograde aortic approach. On the basis of these results, it is only conjecture to suggest that embolism may be associated with a retrograde aortic approach to the LV. However, future studies may help determine if a transseptal rather than a retrograde aortic approach might reduce the risk of emboli. The implications pertaining to catheter technology, procedural approach to the LV, anticoagulation management, and patient risk stratification are severalfold. Clearly, the neurocognitive impact of these cerebral emboli requires further understanding to better assess the risk-benefit ratio before LV ablation, particularly in patients with PVCs undergoing truly elective procedures. In those undergoing LV ablation, identifying mechanisms and risk factors for harmful emboli will ultimately facilitate effective screening strategies as the first step in prevention. For example, transesophageal or intracardiac echocardiography identifying aortic root plaque before accessing the LV might steer an operator toward a transseptal approach. Computed tomography imaging or other peripheral vascular disease screening represents other possible tools that, on the basis of mechanisms and risk factors not yet identified, could function to help assess patients and guide clinical decisions regarding optimal approaches. It may be that procedural factors are more at play than patient factors in increasing risk for cerebral emboli, and the results of the present study necessitate better understanding this. Is a transseptal approach protective relative to the retrograde aortic access to the LV? Should patients be continued on uninterrupted anticoagulation (either on warfarin or a novel anticoagulant, for example) throughout the procedure and during sheath removal? Are certain regions of the LV more prone to coagulation at the site of ablation?
This study has several limitations. Because of a relatively small sample size, we were likely underpowered to identify specific predictors of cerebral emboli among those undergoing LV ablation. Nonetheless, despite a small sample size, this is the first study to demonstrate a previously underappreciated risk of cerebral embolism with LV endocardial ablation, and we believe the proportion of patients exhibiting new brain lesions is remarkable. Patients in the study did not routinely undergo transesophageal echocardiography or computerized axial tomography to assess for aortic atherosclerosis; however, no patients had a history of peripheral vascular disease, only 3 carried a diagnosis of coronary artery disease or aortic vascular disease, and none of those undergoing retrograde aortic approaches had evidence of peripheral vascular disease on their femoral angiogram. Although subclinical disease may have contributed in some patients, there were no clear risk factors identified using the current standard of care.
CONCLUSION
Patients undergoing LV endocardial ablation are at significant risk of cerebral emboli, the significance of which is unknown. In fact, more than half of patients may develop cerebral emboli with LV endocardial ablation, a much larger proportion than that seen in AF despite fewer ablation lesions and ablation to a high-flow cardiac chamber. Future research is critical to understanding the long-term consequences of these lesions and to determine optimal strategies to avoid them.
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